Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda symbols : Nvax save search
Novavax Prepared to Deliver Protein-based Monovalent XBB COVID Vaccine Consistent with FDA VRBPAC Recommendation for the Fall
Published: 2023-06-15 (Crawled : 22:00) - prnewswire.com
NVAX | $3.895 -2.38% -2.44% 3.7M
|
Health Technology
|
| O: 1.74%
H: 1.71%
C: -1.95%
fda covid vaccine
U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster for Adults
Published: 2022-10-19 (Crawled : 15:20) - prnewswire.com
NVAX | $3.895 -2.38% -2.44% 3.7M
|
Health Technology
|
| O: -1.34%
H: 7.24%
C: -2.4%
covid-19 fda grants authorization
FDA Roundup: September 13, 2022
Published: 2022-09-13 (Crawled : 19:00) - fda.gov
NVAX | $3.895 -2.38% -2.44% 3.7M
|
Health Technology
|
| O: 1.2%
H: 5.65%
C: 4.49%
fda
U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Adolescents Aged 12 Through 17
Published: 2022-08-19 (Crawled : 23:00) - prnewswire.com
NVAX | $3.895 -2.38% -2.44% 3.7M
|
Health Technology
| Email alert
Add to watchlist
covid-19 fda grants authorization
Novavax Submits Application to the U.S. FDA for Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Aged 18 and Older
Published: 2022-08-15 (Crawled : 13:20) - biospace.com/
NVAX | $3.895 -2.38% -2.44% 3.7M
|
Health Technology
|
| O: 2.44%
H: 1.6%
C: -0.42%
covid-19 fda application authorization
U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and Over
Published: 2022-07-13 (Crawled : 22:00) - prnewswire.com
NVAX | $3.895 -2.38% -2.44% 3.7M
|
Health Technology
|
| O: -4.42%
H: 2.36%
C: -22.79%
covid-19 fda grants authorization emergency use authorization
Novavax COVID-19 Data Presented at FDA VRBPAC Meeting Demonstrates Broad Antibody Responses to Both Prototype and Omicron-Specific Variants
Published: 2022-06-28 (Crawled : 23:00) - prnewswire.com
NVAX | $3.895 -2.38% -2.44% 3.7M
|
Health Technology
|
| O: -2.27%
H: 6.45%
C: 3.91%
covid-19 fda antibody meeting prototype
FDA Advisory Committee Recommends Emergency Use Authorization of Novavax COVID-19 Vaccine for People Aged 18 Years and Older
Published: 2022-06-07 (Crawled : 22:00) - prnewswire.com
NVAX | $3.895 -2.38% -2.44% 3.7M
|
Health Technology
|
| O: 10.03%
H: 1.22%
C: -4.21%
covid-19 fda vaccine authorization order emergency use authorization
FDA Announces Vaccines and Related Biological Products Advisory Committee Review of Novavax' COVID-19 Vaccine
Published: 2022-04-29 (Crawled : 19:00) - biospace.com/
NVAX | $3.895 -2.38% -2.44% 3.7M
|
Health Technology
|
| O: 3.79%
H: 14.21%
C: -1.92%
covid-19 fda vaccine review
Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine
Published: 2022-01-31 (Crawled : 19:00) - prnewswire.com
NVAX | $3.895 -2.38% -2.44% 3.7M
|
Health Technology
|
| O: 4.0%
H: 1.41%
C: -2.33%
covid-19 fda covid authorization vaccine merge emergency use authorization
Novavax Submits Final Data Packages to U.S. FDA as Prerequisite to Emergency Use Authorization Application Request for COVID-19 Vaccine
Published: 2021-12-31 (Crawled : 19:00) - prnewswire.com
NVAX | $3.895 -2.38% -2.44% 3.7M
|
Health Technology
|
| O: -2.17%
H: 3.53%
C: -5.55%
covid-19 fda application covid authorization vaccine merge emergency use authorization
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.